Andrieu J M, Eme D, Venet A, Audroin C, Tourani J M, Stern M, Israel-Biet D, Beldjord K, Driss F, Even P
Laennec HIV Study Group, Hôpital Laennec, Paris, France.
Clin Exp Immunol. 1988 Jul;73(1):1-5.
Serum HIV (P24) antigen (Ag) measured by an antigen capture ELISA (Abbott) and anti-P24-antibodies (Abs) measured by a competitive ELISA (Abbott) and by Western Blot (Dupont de Nemours) analysis were correlated with lymphocyte subsets (CD4 and CD8) in 174 HIV seropositive patients without AIDS (non-AIDS) and 26 with AIDS. In the non-AIDS group, 27% of the patients were anti-P24-Ab negative and 21% were Ag positive while in the AIDS group these figures were 62% and 54% respectively (P less than 0.001). Overall, a significant correlation exists between the Ab-Ag profile and the CD4 cell count: the percentage of patients with anti-P24-Ab positive and Ag negative decreases from 90% for patients with more than 900 CD4 cells/microliter to 21% for patients with 100 and less CD4 cells/microliter; on the contrary, the percentage of patients with anti-P24-Ab negative and Ag positive increases from 0% over 800 CD4 cells to 53% under 100 CD4 cells/microliter. A weak correlation may also exist with the CD8 cell count. The subgroup of patients with 1,000 or more CD8 cells/microliter have a higher (but not significant) percentage of subjects with Ag positive and anti-P24-Ab negative than the subgroup with less than 1,000 CD8 cells/microliter. A short-term longitudinal study (mean follow-up: 1 year) was performed on 80 non-AIDS subjects: 77% (10/13) of those who had a CD4 cell decrease (greater than 30%) were initially Ag positive, while only 21% (14/67) of those without a decrease were Ag positive at the beginning (P less than 0.1). Although the relative weight and individual predictive value of each of these parameters need to be classified, they are probably the best biological markers currently available for monitoring clinical trials with experimental drugs.
通过抗原捕获酶联免疫吸附测定法（雅培公司）检测血清HIV（P24）抗原（Ag），通过竞争酶联免疫吸附测定法（雅培公司）和蛋白质印迹法（杜邦公司）检测抗P24抗体（Abs），并将其与174例无艾滋病（非艾滋病）的HIV血清阳性患者和26例艾滋病患者的淋巴细胞亚群（CD4和CD8）进行关联分析。在非艾滋病组中，27%的患者抗P24抗体阴性，21%的患者抗原阳性；而在艾滋病组中，这些数字分别为62%和54%（P<0.001）。总体而言，抗体-抗原谱与CD4细胞计数之间存在显著相关性：抗P24抗体阳性且抗原阴性的患者百分比从CD4细胞计数超过900个/微升的患者中的90%降至CD4细胞计数为100个及以下的患者中的21%；相反，抗P24抗体阴性且抗原阳性的患者百分比从CD4细胞计数超过800个时的0%增至CD4细胞计数低于100个/微升时的53%。与CD8细胞计数之间可能也存在弱相关性。CD8细胞计数为1000个或更多/微升的患者亚组中，抗原阳性且抗P24抗体阴性的受试者百分比高于CD8细胞计数低于1000个/微升的患者亚组（但无统计学意义）。对80例非艾滋病受试者进行了一项短期纵向研究（平均随访1年）：CD4细胞减少（超过30%）的受试者中，77%（10/13）最初抗原阳性，而未减少的受试者中，只有21%（14/67）在开始时抗原阳性（P<0.1）。尽管这些参数各自的相对权重和个体预测价值需要分类，但它们可能是目前可用于监测实验药物临床试验的最佳生物学标志物。
